Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SLC18A2 antisense RNA 1 (SLC18A2-AS1) is a long non-coding RNA gene located antisense to the SLC18A2 gene, which encodes the vesicular monoamine transporter 2 (VMAT2)[4][6]. Antisense RNAs typically function to regulate the expression of their corresponding sense gene or neighboring loci by mechanisms involving transcriptional interference, chromatin remodeling, or RNA stability[2]. While SLC18A2 itself is a well-established transporter involved in monoamine neurotransmitter handling and implicated in various neuropsychiatric conditions[1][3][5], current data on SLC18A2-AS1 are limited, with its precise biological and disease roles still unclear. It is categorized as a non-coding RNA and is not itself a therapeutic target, receptor, or enzyme.\n\nIf more specificity about its disease involvement or regulation becomes known, or if a therapeutic targeting approach is developed, those attributes may be updated. Currently, most knowledge applies generally to antisense lncRNAs as a class.
Gene expression modulation via antisense regulation mechanisms (transcriptional interference, chromatin modification, transcript stability)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SLC18A2 antisense RNA 1 (SLC18A2-AS1).